Ernexa Therapeutics reported a net loss of $12.5 million for the nine months ended September 30, 2026, which included a $2.0 million goodwill impairment charge. The company strengthened its cash position to $5.6 million through public offerings and ATM stock issuances, while research and development expenses nearly doubled compared to the prior year.
Ernexa Therapeutics Inc. has made available a formal investor presentation for October 2026. The presentation is intended to provide strategic updates and company information to investors and is accessible via the company's investor relations website.
Ernexa Therapeutics Inc. has made available a new corporate fact sheet and a formal investor presentation for September 2026. The materials, filed under Item 7.01, provide updated corporate information and strategic highlights for investors and are accessible via the company's investor relations website.
Ernexa Therapeutics Inc. appointed Robert J. Spiegel, M.D. to its Board of Directors, effective September 14, 2026. Dr. Spiegel will be compensated according to the company's existing Board of Directors Compensation Plan and will serve until his successor is elected.